Company news

BeOne Medicines Ltd. news in 2026

BeOne Medicines Ltd.'s news releases, calls and decks from 2026, newest first.

View company

(688235)"BEONE MEDICINES LTD."Announcement on Convening the Q3 2026 Performance Briefing

November 2, 2026

(688235)"BEONE MEDICINES LTD."Announcement on Voluntary Disclosure of Holding the Earnings Conference Call

October 22, 2026

Semi-annual Report for 2026

August 26, 2026

Announcement on Convening the 2026 Semi-annual Performance Briefing

August 20, 2026

Announcement on Voluntary Disclosure of Adjustment of Operating Performance Forecast for 2026

August 5, 2026

Announcement on Voluntary Disclosure of Holding Conference Call for Company Performance

July 17, 2026

Grant of Restricted Share Units

July 8, 2026

Voluntary Announcement on Progress of Clinical Trial of BRUKINSA (Zanubrutinib Capsules)

June 30, 2026

Announcement on the Handling of Relevant Tax Matters

June 26, 2026

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

June 1, 2026

BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma

May 13, 2026

Report for Q1 2026

May 11, 2026

BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates

May 6, 2026

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA

April 29, 2026

Announcement on the Record Date for Shareholders' Registration for the 2026 Annual General Meeting

April 28, 2026

Announcement on Signing of Cooperation Agreement and Related Party Transactions

April 27, 2026

BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6

April 22, 2026

Announcement on Realizing Profitability for the 1st Time and Canceling Stock Abbreviation U

April 14, 2026

Announcement on Convening the 2025 Annual Performance Briefing

April 8, 2026

Announcement on Renewing Engagement of Audit Institution for 2026

March 25, 2026

BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership

February 26, 2026

BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26

February 11, 2026

BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

January 13, 2026

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

January 6, 2026

Calls in 2026

Decks in 2026